Lecrolyn (Sodium Cromoglicate)

Sodium cromoglicate acts as a mast cell stabilizer. It binds to calcium channels on mast cells, limiting calcium influx and preventing degranulation. This blocks the release of histamine and other inflammatory mediators that cause the characteristic signs of ocular allergy.

The dosing regimen for Lecrolyn is determined by the prescribing clinician. Typically, the prescriber will advise the number of drops per eye and the frequency of administration based on the severity of the allergic condition and the patient’s response.

Safety data for sodium cromoglicate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lecrolyn.

To order Lecrolyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lecrolyn’s active ingredient, sodium cromoglicate, is a mast cell stabilizer, whereas many other ocular antiallergics are antihistamines or combination products. Mast cell stabilizers act upstream by preventing mediator release, offering a complementary mechanism that can be used alone or with antihistamine drops for broader symptom control.

Lecrolyn should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed when not in use and retain it in its original packaging to protect the formulation from contamination.

Lecrolyn is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and instill the prescribed number of drops. The eye should be closed gently for a few seconds to allow the solution to spread.

While most reactions are mild, serious adverse events can include allergic contact dermatitis, corneal ulceration, and, in extremely rare cases, anaphylaxis. Any sudden increase in pain, vision loss, or systemic allergic symptoms should prompt immediate medical evaluation.

Lecrolyn should be avoided in individuals with a known hypersensitivity to sodium cromoglicate or any excipients in the formulation. It is also contraindicated in eyes with active infection until the infection has been treated, and patients should consult a clinician before use if they have severe ocular surface disease.